Genetically Modified Primary Cells for Allogeneic Cell Therapy

Patent/Application Number: US20240010988A1
Filing Date: January 10, 2024 (publication date early 2024; actual filing was shortly before)
Publication Date: Published in 2024
Assignee / Applicant: Sana Biotechnology, Inc.
Title: Genetically modified primary cells for allogeneic cell therapy
Focus: Engineered hypoimmunogenic primary cells designed to evade immune rejection for use in cell therapy.

What This Patent Covers

This patent application claims engineered primary cells — such as stem cells, islet cells, T cells, NK cells, and other therapeutic cell types — that have been genetically modified to evade immune rejection when administered into a genetically mismatched recipient. The core innovation is the combination of genetic changes that reduce or silence major histocompatibility complex (MHC) class I/II molecules and increase expression of tolerogenic factors to create hypoimmunogenic cells suitable for allogeneic (donor‑to‑recipient) transplantation without chronic immunosuppression.

Hypoimmunogenic primary cells: Cells genetically altered to reduce expression of one or more MHC class I and/or class II proteins, thereby lowering immune‑mediated rejection.
Increased tolerogenic factors: Modifications to enhance expression of proteins (e.g., CD47 and other tolerogenic modulators) that signal immune cells to tolerate the transplanted cells.
Broad cell types: The claims encompass numerous primary cell types — including pancreatic islet cells, beta islet cells, T cells, NK cells, endothelial cells, hepatocytes, and others — making the technology applicable to many therapeutic areas.
Therapeutic methods: Methods of preparing and administering these engineered cells as pharmaceutical compositions to treat diseases or deficiencies by replacing damaged or deficient cells in a patient.

Why This Patent Is Important

Core to Sana’s Therapeutic Strategy: Sana is developing allogeneic cell therapies that can be transplanted into patients without triggering immune rejection — a major hurdle in cell therapy. This patent application underpins that strategy by claiming the foundational genetic modifications needed for immune evasion.
Broad Clinical Utility: Because the claims cover many cell types (e.g., islet cells for diabetes, immune cells for cancer, or stem cells for regenerative medicine), this IP could support multiple future product lines and multi‑billion‑dollar markets.
Enables Off‑the‑Shelf Cell Therapies: Hypoimmunogenic cells could be administered broadly without matching donor and recipient or lifelong immunosuppression, dramatically reducing costs and complications compared with current approaches.
Potential for Licensing/Partnership: This foundational platform could be licensed to other biotech companies seeking to build immune‑evasive cell products, creating additional revenue beyond Sana’s own pipelines.

Summary

U.S. Patent Application US20240010988A1 represents one of Sana Biotechnology’s most important patent filings, covering genetically engineered hypoimmunogenic primary cells designed for allogeneic cell therapies that evade immune rejection. It underpins the company’s core cell therapy platform — enabling potentially broad therapeutic applications (e.g., diabetes, immune modulation, regenerative medicine) and strong commercial value if these technologies reach clinical and market success.

BioTech IP Review